In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Tevas push into differentiated CNS therapies
Does semaglutide have any side effects
At Madison Integrative Medicine, we offer B12 treatments as part of our broader IV therapy options
Fuel your body (and weight loss) with whole foods high in fiber, protein, and healthy fats
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled